Key facts
- This page summarizes Brian G. Atwood's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 07 Feb 2025, 17:23.
Brian G. Atwood - 07 Feb 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Reporting relationship
- Director
- Issuer ticker
- CERO
- Reported as of
- 07 Feb 2025
- Net transaction value
- +$999,992
- SEC form
- 4
- Accepted by SEC
- 07 Feb 2025, 17:23:22 UTC
- Prior SEC filing
- 04 Dec 2024
- Next SEC filing
- 26 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian G. Atwood
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian G. Atwood filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 07 Feb 2025.
Change
- Previous filing in this sequence was filed on 04 Dec 2024.
- Current net transaction value: +$999,992.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERO
transaction
Derivative
Pre-Funded Warrant
Award
- Transaction value
- $30.61
- Shares
- +306,120
- Change %
- Price
- $0.000100
- Shares after
- 306,120
- Date
- 07 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 306,120
- Exercise price
- $0.000100
- Footnotes
- F1
CERO
transaction
Derivative
Pre-Funded Warrant
Award
- Transaction value
- $20.41
- Shares
- +204,080
- Change %
- Price
- $0.000100
- Shares after
- 204,080
- Date
- 07 Feb 2025
- Ownership
- By GVN, LLC
- Underlying class
- Common Stock
- Underlying amount
- 204,080
- Exercise price
- $0.000100
- Footnotes
- F1, F2
CERO
transaction
Derivative
Warrant to Purchase Shares of Common Stock
Award
- Transaction value
- $599,965
- Shares
- +306,120
- Change %
- Price
- $1.96
- Shares after
- 306,120
- Date
- 07 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 306,120
- Exercise price
- $1.96
- Footnotes
- F1
CERO
transaction
Derivative
Warrant to Purchase Shares of Common Stock
Award
- Transaction value
- $399,976
- Shares
- +204,080
- Change %
- Price
- $1.96
- Shares after
- 204,080
- Date
- 07 Feb 2025
- Ownership
- By GVN, LLC
- Underlying class
- Common Stock
- Underlying amount
- 204,080
- Exercise price
- $1.96
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the "Issuer"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the "Stockholder Approval Date") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date.
Footnote F2
GVN, LLC (the "LLC") is a limited liability company of which the sole member is the Atwood-Edminster Trust dtd 4-2-2000 (the "Trust"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC.